SI
AXSM icon

Scout Investments’s Axsome Therapeutics AXSM Stock Holding History

Scout Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.24M Sell
59,878
-9,680
-14% -$845K 0.14% 164
2024
Q2 		$5.6M Buy
+69,558
New +$5.15M 0.15% 170

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Scout Investments's AXSM Position: Q3 2024 in Review

Scout Investments reduced its Axsome Therapeutics (AXSM) stake by 14% in Q3 2024, selling an estimated $845K and leaving 59,878 shares worth $5.24M. The position accounts for 0.14% of the portfolio, ranked #164.

Scout Investments first reported a position in AXSM in Q2 2024 and has held it in 2 quarters since. The position peaked at $5.6M in Q2 2024. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Scout Investments held 59,878 shares of Axsome Therapeutics worth $5.24M as of Q3 2024.
  • Scout Investments sold 9,680 Axsome Therapeutics shares in Q3 2024, an estimated $845K.
  • Axsome Therapeutics made up 0.14% of Scout Investments's portfolio in Q3 2024, its #164 holding.
  • Scout Investments first reported a position in Axsome Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Scout Investments's Axsome Therapeutics position peaked at $5.6M in Q2 2024.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Scout Investments's 13F filing for Q3 2024, filed 12 Nov 2024.